Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lisocabtagene maraleucel shows effectiveness in transplant ineligible r/r DLBCL, FL

Key clinical point: Elderly and/or comorbid patients with r/r aggressive large B-cell NHL, ineligible for high-dose chemotherapy and HSCT, can receive liso-cel with safety and efficacy.

Major finding: At a median follow-up of 3.5 months, the overall response rate was 80% (95% confidence interval, 59–93; n=20); 48% of patients (n=12) achieved complete response.

Study details: Open-label, phase 2 PILOT study is the first to assess the safety and efficacy of liso-cel as second-line therapy in transplant noneligible patients

Disclosures: The abstract contained no conflict information.

Citation:

Ghosh N et al. European Hematology Association virtual annual meeting. 2020; Abstract S244.